Boardroom Alpha
Boardroom Alpha
PTGX · Additional Proxy Materials (DEFA14A) · Filed April 28, 2026

Protagonist Therapeutics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 28, 2026
Ticker
PTGX
Accession
0001104659-26-050440
Boardroom Alpha · Filing insights

Protagonist Therapeutics, Inc. board recommends all four proposals for the 2026 annual meeting, including two Class I director nominees.

About Protagonist Therapeutics Inc
Market cap
$9.7B
1Y TSR
+166.4%
3Y TSR
+97.4%
Board grade
B+
Sector
Healthcare
CEO
Dinesh V Ph D Patel
Last annual meeting: Jun 17, 2026 · View full Protagonist Therapeutics Inc profile →

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

 

(Amendment No.              )

 

Filed by the Registrant x

 

Filed by a Party other than the Registrant ¨

 

Check the appropriate box:

 

¨ Preliminary Proxy Statement
   
¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
¨ Definitive Proxy Statement
   
x Definitive Additional Materials
   
¨ Soliciting Material under §240.14a-12

 

PROTAGONIST THERAPEUTICS, INC.

 

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

x No fee required.
   
¨ Fee paid previously with preliminary materials.
   
¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

GRAPHIC

Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V95678-P50686 *Please check the meeting materials for any special requirements for meeting attendance. PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD. SUITE 140 NEWARK, CA 94560 PROTAGONIST THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 16, 2026 11:59 PM ET Vote Virtually at the Meeting* June 17, 2026 10:00 AM PT Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 3, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Before the Meeting by Internet: To vote now by internet, go to www.proxyvote.com. Have the control number that is printed in the box available and follow the instructions. Vote Before the Meeting by Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card. Vote Virtually at the Meeting: To vote during the Meeting go to www.virtualshareholdermeeting.com/PTGX2026. Have the control number that is printed in the box available and follow the instructions. You invested in PROTAGONIST THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 17, 2026.

GRAPHIC

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V95679-P50686 THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials at www.proxyvote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote on these important matters. 1. To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified. Nominees: For 01) Dinesh V. Patel, Ph.D. 02) Lewis T. “Rusty” Williams, M.D., Ph.D. 2. To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. For 3. To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026. For 4. To approve the adoption of the Company’s 2026 Equity Incentive Plan. For NOTE: Such other business as may properly come before the meeting or any adjournment or postponement thereof. The Board of Directors knows of no other matters that are expected to be presented for consideration at the 2026 Annual Meeting of Stockholders. If any other matters are properly brought before the 2026 Annual Meeting of Stockholders or any postponement or adjournment thereof, it is the intention of the proxies named in the proxy card to vote on such matters in accordance with their best judgment.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Protagonist Therapeutics Inc (PTGX)

Reference

Frequently asked questions

When did Protagonist Therapeutics Inc file this DEFA14A?
Protagonist Therapeutics Inc (PTGX) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 28, 2026. The accession number assigned by EDGAR is 0001104659-26-050440.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Protagonist Therapeutics, Inc. board recommends all four proposals for the 2026 annual meeting, including two Class I director nominees. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Protagonist Therapeutics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Protagonist Therapeutics Inc has filed under CIK 1377121, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer